Gambro and DaVita reach agreement on Amended Alliance and Product Supply Agreement
Gambro AB, Gambro Renal Products, Inc. and DaVita Inc. have agreed to an amended and restated Alliance and Product Supply Agreement. This amendment effectively revokes the termination notice which was provided by DaVita in May primarily as a result of Gambro Renal Products' inability to supply monitors due to the current Import Alert declared by the FDA.
"We are pleased to have reached this agreement with DaVita," says Jon Risfelt, President Gambro Renal Products. "DaVita is a very important customer for us and now we can focus on meeting its long-term needs and the needs of the thousands of patients DaVita serves."
The Supply Agreement was originally entered into as part of the agreement to divest Gambro's U.S. dialysis clinics to DaVita in October 2005. Under the amendment, Gambro will continue to be the preferred supplier of renal products to DaVita.
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.